Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty

Catheterization and Cardiovascular Interventions

Volumn 76, Issue 6, 2010, Pages 787-793

  Tanzilli, Gaetano ^a   Greco, Cesare ^a   Pasceri, Vincenzo ^b   Pelliccia, Francesco ^b   Arrivi, Alessio ^a   Placanica, Attilio ^a   Mangieri, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

acute myocardial infarction; adenosine; angioplasty; no reflow; trial; vasoconstriction; vasodilation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ATROPINE; CLOPIDOGREL; DIPYRIDAMOLE; GLYCERYL TRINITRATE; HEPARIN; VERAPAMIL;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; HEART MUSCLE PERFUSION; HUMAN; INTRACORONARY DRUG ADMINISTRATION; MALE; NO REFLOW PHENOMENON; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DIPYRIDAMOLE; DRUG SUBSTITUTION; FEMALE; HUMANS; INFUSIONS, PARENTERAL; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL PERFUSION IMAGING; NO-REFLOW PHENOMENON; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STENTS; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; VERAPAMIL;

EID: 78649659466     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22724     Document Type: Article

References (29)

1. Keeley EC, Boura JA, Grines CL,. Primary angioplasty versus intravenous throbolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
2. Rezkalla SH, Kloner RA,. No-reflow phenomenon. Circulation 2002; 105: 656-662.
3. Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, Safian RD,. No-reflow after percutaneous coronary intervention: Clinical and angiographic characteristics, treatment and outcome. Am J Cardiol 1995; 75: 778-782.
4. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T,. Clinical implications of the "no-reflow" phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-228.
5. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, Kondo J, Tsuboi H, Sassa H,. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-1209.
6. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CD, Popma JJ, Piana R,. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-46.
7. Reffelmann T, Kloner RA,. The no-reflow phenomenon: Basic science and clinical correlates. Heart 2002; 87: 162-168.
8. Mongeon FP, Belisle P, Joseph L, Eisenberg MJ, Rinfret S,. Adjunctive thrombctomy for acute myocardial infarction. A bayesan meta-analysis. Circ Cardiovasc Interv 2010; 3: 6-16.
9. Marzilli M, Orsini E, Marraccini P, Testa R,. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-2159.
10. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, Nishikawa N, Higashino Y, Fujii K, Minamino T,. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-1199.
11. Huang RI, Patel P, Walinsky P, Fischman DL, Ogilby JD, Awar M, Frankil C, Savage MP,. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 68: 671-676.
12. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, Pironi B, Capasso M, Richichi G,. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005; 95: 1358-1361.
13. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F,. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv 2008; 71: 283-289.
14. Kim HH, Liao JK,. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39-s42.
15. Movahed MR, Butman SM,. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention. Cardiovasc Revasc Med 2008; 9: 56-61.
16. Fischell TA,. Pharmaceutical interventions for the management of no-reflow. J Invasive Cardiol 2008; 20: 374-379.
17. Werner GS, Lang K, Kuehnert H, Figulla HR,. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57: 444-451.
18. Gibson MC, Schomig A,. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109: 3096-3105.
19. Kotani J, Nanto S, Mintz GS, Kitakaze M, Ohara T, Morozumi T, Nagata S, Hori M,. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002; 106: 1672-1677.
20. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, Hong MK, Kim BK, Oh SJ, Jeon DW, Yang JY, Cho JR, Lee NH, Cho YH, Cho DK, Jang Y,. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: The STATIN STEMI trial. JACC Cardiovasc Interv 2010; 3: 332-339.
21. Sakuma T, Motoda C, Tokuyama T, Oka T, Tamekiyo H, Okada T, Otsuka M, Okimoto T, Toyofuku M, Hirao H, Muraoka Y, Ueda H, Masaoka Y, Hayashi Y,. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients with acute anterior myocardial infarction: A study using myocardial contrast echocardiography. Int J Cardiol 2010; 140: 200-209.
22. German DC, Kredich NM, Bjornsson TD,. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther 1989; 45: 80-84.
23. Schoeffter P, Lugnier C, Demesy-Waeldele F, Stoclet JC,. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem Pharmacol 1987; 36: 3965-3972.
24. Neri Serneri GG, Masotti G, Poggesi L, Galanti G, Morettini A,. Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol 1981; 21: 9-15.
25. Iuliano L, Colavita AR, Camastra C, Bello V, Quintarelli C, Alessandroni M, Piovella F, Violi F,. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol 1996; 119: 1438-1446.
26. Kusmic C, Picano E, Busceti CL, Petersen C, Barsacchi R,. The antioxidant drug dipyridamole spares the vitamin E and thiols in red blood cells after oxidative stress. Cardiovasc Res 2000; 47: 510-514.
27. Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO,. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241.
28. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ, Jessurun GA, Anthonio RL, van den Heuvel AF, Tan ES, Zijlstra F,. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: A randomized controlled trial. Circ Cardiovasc Interv 2009; 2: 323-329.
29. Hang CL, Wang CP, Yip HK, Yang CH, Guo GB, Wu CJ, Chen SM,. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest 2005; 128: 2593-2598.